{"id":105288,"date":"2020-04-13T15:43:02","date_gmt":"2020-04-13T22:43:02","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/04\/regeneron-granted-fundamental-patents-covering-mouse-antibody-technology-used-in-velocimmune-mice"},"modified":"2020-04-13T15:43:02","modified_gmt":"2020-04-13T22:43:02","slug":"regeneron-granted-fundamental-patents-covering-mouse-antibody-technology-used-in-velocimmune-mice","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/04\/regeneron-granted-fundamental-patents-covering-mouse-antibody-technology-used-in-velocimmune-mice","title":{"rendered":"Regeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used in VelocImmune\u00ae Mice"},"content":{"rendered":"<p>Circa 2013<\/p>\n<p>These patents form part of Regeneron\u2019s global patent portfolio, which together protect fundamental inventions behind Regeneron\u2019s <i>VelocImmune<\/i> humanized mice. The two patents listed above specifically contain claims covering genetically modified mice that have unrearranged human immunoglobulin variable region gene segments at endogenous mouse immunoglobulin loci. The <i>VelocImmune<\/i> mice contain the full repertoire of human heavy chain immunoglobulin genes and kappa light chain genes, each linked to endogenous mouse constant regions. As a result, <i>VelocImmune<\/i> mice generate a normal and robust immune response which many believe is becoming the gold standard for making human antibody therapeutics. <i>VelocImmune<\/i> is also proving to be one of the most valuable technologies in biotechnology history, in terms of the licensing and collaboration revenues it has helped generate.<\/p>\n<hr>\n<p>TARRYTOWN, N.Y., Aug. 7, 2013 \/PRNewswire\/ \u2014 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United States Patent and Trademark Office granted U.S. Patent No. 8,502,018 relating to methods of genetically modifying a mouse to make human antibodies. A similar European.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Circa 2013 These patents form part of Regeneron\u2019s global patent portfolio, which together protect fundamental inventions behind Regeneron\u2019s VelocImmune humanized mice. The two patents listed above specifically contain claims covering genetically modified mice that have unrearranged human immunoglobulin variable region gene segments at endogenous mouse immunoglobulin loci. The VelocImmune mice contain the full repertoire of [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-105288","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/105288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=105288"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/105288\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=105288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=105288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=105288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}